Plewig G, Hennes R, Maas B, Mack-Hennes A
Z Hautkr. 1986 Sep 1;61(17):1205-10.
64 patients suffering from severe papulopustular acne previously resistant to therapy were treated with 13-cis retinoic acid (isotretinoin) at a dosage of 0.05, 0.1, or 0.2 mg/kg body weight for 20 weeks. After treatment, we performed follow-up examinations for 12 months concerning remission and side effects. After six months, more than half of the patients were free of relapses, even those treated with low doses, although there was a trend in favor of the 0.2 mg/kg body weight dose. According to lesion counts, the therapeutic effect of isotretinoin was even better after discontinuation of the drug. Mucocutaneous side effects disappeared within four to six weeks. In severe papulopustular acne, previously showing inadequate response to therapy, at least 0.2 mg/kg body weight isotretinoin should be given to ensure a good therapeutic result. These findings correspond with those observed in the initial reduction of lesions.
64例先前治疗抵抗的重度丘疹脓疱性痤疮患者，接受了剂量为0.05、0.1或0.2mg/kg体重的13-顺式维甲酸（异维甲酸）治疗，为期20周。治疗后，我们针对缓解情况和副作用进行了为期12个月的随访检查。六个月后，超过半数患者未复发，即使是低剂量治疗的患者，尽管有趋势表明0.2mg/kg体重剂量效果更佳。根据皮损计数，停药后异维甲酸的治疗效果更佳。黏膜皮肤副作用在4至6周内消失。对于先前治疗反应欠佳的重度丘疹脓疱性痤疮，应给予至少0.2mg/kg体重的异维甲酸以确保良好的治疗效果。这些发现与最初皮损减少时观察到的情况相符。
